- Austria (Website)
- Czech Republic (Website)
- Denmark (Website)
- Finland (Website)
- France (Website)
- Germany (Website)
- Hungary (Website)
- Italy (Website)
- Ivory Coast
Business review for the nine months ended September 30, 201818 October, 2018
Marcy l'Étoile, October 18, 2018 – bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the nine months ended September 30, 2018.
bioMérieux’s consolidated sales amounted to €1,749 million for the nine months ended September 30, 2018, versus €1,674 million for the same period one year earlier. Sales grew by 9.8% year-on-year at constant exchange rates and scope of consolidation. As expected, currency effects remained negative in third-quarter 2018 but weighed less on reported growth, with sales for the first nine months of the year up 4.5% compared to the same period in 2017.
- Strong sales dynamic confirmed in third quarter, with an 8.8% increase in organic sales
- Growth of 9.8% at constant exchange rates and scope of consolidation over the nine months ended September 30:
- €1,749 million in sales
- Up 4.5% as reported
- Ramp-up in business on the back of three key growth drivers: molecular biology with the BIOFIRE® product line, activity in the Asia Pacific region, and industrial applications.
Alexandre Mérieux, Chairman and Chief Executive Officer, said: “bioMérieux delivered another robust sales performance in the third quarter of 2018, with organic growth nearing 9%. These positive dynamics place the Group on track to achieving its financial objectives for the year.”
A world leader in the field of in vitro diagnostics for over 50 years, bioMérieux is present in more than 150 countries through 43 subsidiaries and a large network of distributors. In 2017, revenues reached €2.3 billion, with over 90% of international sales.
bioMérieux provides diagnostic solutions (systems, reagents, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
bioMérieux is listed on the Euronext Paris stock market.
Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP
Corporate website: www.biomerieux.com. Investor website: www.biomerieux-finance.com
Tel.: +33 (0)4 78 87 22 37
Tel.: +33 (0)4 78 87 20 53
Tel.: +33 (0)1 53 70 74 64
Tel.: +33 (0)1 53 70 74 48
Download the Full Press Release: